FTD-GRN

Clinical trials for FTD-GRN explained in plain language.

Never miss a new study

Get alerted when new FTD-GRN trials appear

Sign up with your email to follow new studies for FTD-GRN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 2

Gene therapy infused directly into brain aims to halt rare dementia

Disease control Recruiting now

This early-phase trial tests a gene therapy called AVB-101 for people with frontotemporal dementia caused by GRN gene mutations. The therapy delivers a working copy of the GRN gene directly into the brain during a one-time procedure. The study will enroll 18 adults aged 30-75 to …

Matched conditions: FTD-GRN

Phase: PHASE1, PHASE2 • Sponsor: AviadoBio Ltd • Aim: Disease control

Last updated Jun 27, 2026 12:06 UTC

FTD-GRN

Get alerted when new FTD-GRN trials appear

Gene therapy infused directly into brain aims to halt rare dementia